Proteinase Patents (Class 435/219)
  • Patent number: 11325960
    Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: May 10, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Masashi Shimizu, Toshitaka Sato, Yoshihisa Arita
  • Patent number: 11168123
    Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: November 9, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Masashi Shimizu, Toshitaka Sato, Yoshihisa Arita
  • Patent number: 11001821
    Abstract: The present invention relates to isolated polypeptides having protease activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: May 11, 2021
    Assignee: NOVOZYMES A/S
    Inventors: Astrid Benie, Morten Gjermansen, Peter Rahbek Oestergaard
  • Patent number: 10787656
    Abstract: The invention is directed to novel alkaline proteases.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: September 29, 2020
    Assignee: Fomia BioSolutions, Inc.
    Inventors: Goutami Banerjee, Jie Yang, Khin Oo, Xiyun Zhang, Eric Lin Hu, Imad N. Sawaya
  • Patent number: 10731147
    Abstract: The disclosure relates to methods for nucleic acid purification, comprising (a) combining a sample comprising at least one nucleic acid with a binding buffer comprising at least one magnetic particle and having a pH ranging from about 4 to about 10 to form a solution; (b) incubating the sample with the binding buffer for a time period sufficient to reversibly bind the at least one nucleic acid to the at least one magnetic particle to form at least one modified magnetic particle, (c) separating the at least one modified magnetic particle from the solution, (d) washing the at least one modified magnetic particle with at least one wash buffer; and (e) combining the at least one modified magnetic particle with an elution buffer Kits comprising these buffers and magnetic particles are also disclosed herein.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: August 4, 2020
    Assignee: Corning Incorporated
    Inventors: Yi-Cheng Hsieh, Cheng-I Hsu, Chia-Ling Wu, Hsan Jan Yen
  • Patent number: 10683362
    Abstract: Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to improved recombinant immunotoxins comprising anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and a Pseudomonas Exotoxin moiety which has been modified to reduce its immunogenicity and protease sensitivity and providing a better cytotoxicity for cells which express mesothelin. The RITs are well-suited for the treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: June 16, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Ira H. Pastan, John Weldon, Richard Beers
  • Patent number: 10662398
    Abstract: Low-pH automatic dishwashing detergent composition having a pH as measured in 1% weight aqueous solution at 25° C. of from about 5 to about 7.5 and comprising a protease selected from the group consisting of: (i) a metalloprotease; (ii) a cysteine protease, (iii) an aspartate protease, and mixtures thereof.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: May 26, 2020
    Assignee: The Procter & Gamble Company
    Inventors: Alan Thomas Brooker, Philip Frank Souter, Colin Ure, Craig Adam Wilkinson, Lindsay Suzanne Bewick
  • Patent number: 10662231
    Abstract: The present disclosure pertains to methods of producing recombinant peptides that contain between 10 and 200 amino acid residues using novel carrier proteins derived from superfolder green fluorescent protein and its mutants.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: May 26, 2020
    Assignee: SUZHOU KUNPENG BIOTECH CO., LTD.
    Inventors: Wenshe Liu, Wei Wan
  • Patent number: 10647974
    Abstract: The present invention relates to novel subtilase variants exhibiting increased stability and optionally on par or improved wash performance. The variants of the invention are suitable for use in e.g. cleaning or detergent compositions, such as laundry detergent compositions and dish wash compositions, including automatic dish wash compositions. The present invention also relates to isolated DNA sequences encoding the variants, expression vectors, host cells, and methods for producing and using the variants of the invention.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: May 12, 2020
    Assignee: Novozymes A/S
    Inventors: Jens Erik Nielsen, Pernille Ollendorff Hede, Jurgen Carsten Franz Knotzel, Maria Norman Hockauf, Lars Beier, Mikael Bauer, Annette Helle Johansen, Lars Lehmann Hylling Christensen, Julie Bille Rannes
  • Patent number: 10610602
    Abstract: Disclosed is a drug conjugate as a prodrug that is degraded by cathepsin B specifically expressed in tumor tissues to release doxorubicin. The drug conjugate can form self-assembled nanoparticles. In addition, the drug conjugate specifically responds to and is activated in tumor cells. Therefore, the use of the drug conjugate eliminates the incidence of side effects (for example, cell damage and apoptosis) during the course of cancer prevention or treatment.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: April 7, 2020
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Kwangmeyung Kim, Ick Chan Kwon, Juho Park
  • Patent number: 10596201
    Abstract: An acellular soft tissue-derived matrix includes a collagenous tissue that has been delipidated and decellularized. Adipose tissue is among the soft tissues suitable for manufacturing an acellular soft tissue-derived matrix. Exogenous tissuegenic cells and other biologically-active factors may be added to the acellular matrix. The acellular matrix may be provided as particles, a slurry, a paste, a gel, or in some other form. The acellular matrix may be provided as a three-dimensional scaffold that has been reconstituted from particles of the three-dimensional tissue. The three-dimensional scaffold may have the shape of an anatomical feature and serve as a template for tissue repair or replacement. A method of making an acellular soft tissue-derived matrix includes steps of removing lipid from the soft tissue by solvent extraction and chemical decellularization of the soft tissue.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: March 24, 2020
    Assignee: Musculoskeletal Transplant Foundation
    Inventors: Yen-Chen Huang, Asia Ivery, Bryan Choi, Benjamin Schilling, Manh-Dan Ngo
  • Patent number: 10465182
    Abstract: Methods and reagents are provided for the rapid extraction of nucleic acids from a cell or tissue sample. In certain embodiments the sample comprises a formalin fixed paraffin embedded sample (e.g., a FFPET sample), or a fine needle aspirate and/or a cell/tissue smear. In some embodiments, the methods comprise incubating one or more sections of said tissue sample in a lysis solution comprising a buffer sufficient to maintain the pH of said solution at a pH ranging from about pH 4 to about pH 9; a chaotropic agent; a chelating agent; and a detergent; where the incubating is at a temperature ranging from about 50° C. to about 100° C.; and recovering the nucleic acid from said lysis solution.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: November 5, 2019
    Assignee: CEPHEID
    Inventor: Kenneth E. Ho
  • Patent number: 10435752
    Abstract: The present invention relates to: a composition for detecting a gastric cancer marker comprising a preparation for measuring the expression level or methylation level of mRNA of ADCY3 or a protein thereof; a kit for diagnosing gastric cancer, containing the composition; a method for diagnosing gastric cancer by treating a biological sample with the preparation to ascertain whether a material for complementarily binding to the preparation exists and comparing the amount thereof with a control group; a composition for treating and preventing gastric cancer, containing a preparation capable of inhibiting ADCY3 polynucleotide or ADCY3 polypeptide; and a method for treating gastric cancer by administering the composition to an individual. According to the present invention, it is possible to diagnose gastric cancer with high diagnostic sensitivity and specificity using ADCY3 as a marker for diagnosing gastric cancer, and thus can greatly contribute to reducing mortality due to gastric cancer.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: October 8, 2019
    Assignee: NATIONAL CANCER CENTER
    Inventors: Yeon Su Lee, Sung Ho Goh, In Hoo Kim, Seung Hyun Hong
  • Patent number: 10364428
    Abstract: The disclosure relates to methods for nucleic acid purification, comprising (a) combining a sample comprising at least one nucleic acid with a binding buffer comprising at least one magnetic particle and having a pH ranging from about 4 to about 10 to form a solution; (b) incubating the sample with the binding buffer for a time period sufficient to reversibly bind the at least one nucleic acid to the at least one magnetic particle to form at least one modified magnetic particle, (c) separating the at least one modified magnetic particle from the solution, (d) washing the at least one modified magnetic particle with at least one wash buffer; and (e) combining the at least one modified magnetic particle with an elution buffer Kits comprising these buffers and magnetic particles are also disclosed herein.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: July 30, 2019
    Assignee: Corning Incorporated
    Inventors: Yi-Cheng Hsieh, Cheng-I Hsu, Chia-Ling Wu, Hsan-Jan Yen
  • Patent number: 10351610
    Abstract: This disclosure concerns compositions and methods for increasing the expression of a polynucleotide of interest. Some embodiments concern novel transactivation polypeptides and variants thereof that have been identified in plants, and methods of using the same. Particular embodiments concern the use of at least one DNA-binding polypeptide in a fusion protein to target at least one transactivation polypeptide or variant thereof to a specific binding site on a nucleic acid comprising the polynucleotide of interest, such that its expression may be increased.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: July 16, 2019
    Assignee: Dow AgroSciences LLC
    Inventors: Joseph Petolino, Jianquan Li, Steven L Evans, Ryan C Blue
  • Patent number: 10342847
    Abstract: The present invention relates to compositions and methods for preventing and reducing inflammation and preventing and treating diseases and disorders associated with inflammation. It has been shown that CRADD plays a pivotal role in maintaining the integrity of endothelial monolayers. The recombinant cell-penetrating CRADD protein (CP-CRADD)-based compositions and methods described herein provide for the development of a novel treatment for inflammatory vascular disorders including cardiovascular, cerebrovascular, respiratory, gastrointestinal, and renal systems.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: July 9, 2019
    Assignee: Vanderbilt University
    Inventors: Jack J. Hawiger, Ruth Ann Veach, Yan Liu, Huan Qiao, Lukasz S. Wylezinski
  • Patent number: 10274405
    Abstract: A method for deparaffinizing an FFPE tissue sample comprises mixing the FFPE tissue sample with an organic solvent to form a first mixture (10). A surfactant is added to the first mixture (10) to form a second mixture. The second mixture is separated into an organic solvent layer (11) and a surfactant layer (12). The surfactant layer (12) comprises a deparaffinized tissue sample from the FFPE tissue sample. The method also comprises adding water or an aqueous solution to the separated second mixture to form an organic solvent layer (11), a water or aqueous solution layer (13) and a surfactant layer (12). This surfactant layer comprises the deparaffinized tissue sample.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: April 30, 2019
    Assignee: EXSCALE BIOSPECIMEN SOLUTIONS AB
    Inventors: Lucy Mathot, Karin Hartman, Tobias Sjöblom
  • Patent number: 10208301
    Abstract: The present invention relates to xylanase variants, polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; compositions comprising the xylanase variants and methods of using the variants.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: February 19, 2019
    Assignee: Novozymes A/S
    Inventors: Steffen Danielsen, Peter Kamp Hansen, Frank Winther Rasmussen, Roland Alexander Pache
  • Patent number: 10202594
    Abstract: The present invention relates to a polypeptide having proline-specific endoprotease activity, wherein the polypeptide has less than 70% residual activity when the polypeptide has been kept at a temperature of 65° C. for 15 min.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: February 12, 2019
    Assignee: DSM IP ASSETS B.V.
    Inventors: Jan Metske Van Der Laan, Peter Jozef Ida Van De Vondervoort, Chantal Christis, Martine Spaans, Angela De Bruine-Paulus
  • Patent number: 10150957
    Abstract: The present invention relates to protease variants and methods for obtaining protease variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: December 11, 2018
    Assignee: Novozymes A/S
    Inventors: Frank Winther Rasmussen, Rolf Thomas Lenhard, Miguel Duarte Guilherme Perreira Toscano, Esben Peter Friis, Signe Eskildsen Larsen, Jurgen Carsten Franz Knotzel, Mikael Bauer
  • Patent number: 10144923
    Abstract: To provide a method for producing a horseshoe crab recombinant Factor C. The horseshoe crab recombinant Factor C is produced through expression thereof by use of mammalian cells such as CHO DG44 and HEK293 as host cells.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: December 4, 2018
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Hikaru Mizumura, Toshio Oda, Shun-ichiro Kawabata
  • Patent number: 10030239
    Abstract: The present invention relates to isolated polypeptides having protease activity, and polynucleotides encoding the polypeptides. The invention further relates to the use of such polypeptides in detergent and/or in cleaning processes. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing the polypeptides.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: July 24, 2018
    Assignee: Novozymes A/S
    Inventor: Morten Gjermansen
  • Patent number: 10004775
    Abstract: An extract of Carica papaya leaves obtained from a plant of age six months and younger from the date of germination of the seed is used as an inhibitor of HIF to effectively block hypoxia-inducible factor (HIF) function and methods of use thereof. More specifically it relates to the use of the Carica papaya plant extract to eliminate unwanted cells by inhibiting HIF in the prevention and treatment of hypoxia-related conditions and diseases such as inflammatory diseases, vascular diseases, cancer and infectious diseases. In a particular embodiment, a solid hypoxic tumor in a patient is treated by administering to the patient a therapeutically acceptable amount of an extract of Carica papaya leaves obtained from a plant of age six months and younger from the date of germination of the seed, preferably an alcohol extract such as a methanol extract, whereby to inhibit hypoxia-inducible factors in the tumor.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: June 26, 2018
    Assignees: The Regents of the University of California, Universiti Putra Malaysia
    Inventors: Eric J. Stanbridge, Norazizah Shafee, Khatijah Yusoff
  • Patent number: 9974321
    Abstract: Disclosed are a fish protein oligopeptide with low allergenicity and slight fishiness, and industrial preparation method and application thereof. The method comprises the following steps: 1) washing fresh fish flesh and/or fish wastes, crushing, and adding water to obtain a mixture; 2) performing thermal denaturation on the mixture to obtain a denaturized protein solution; 3) centrifuging the denaturized protein solution to obtain a precipitate, and adding water into the precipitate and grinding, to obtain a slurry; 4) adjusting the slurry to pH 6-9, and sequentially adding a neutral protease, a papain and an alkaline protease to conduct enzymolysis, and after enzyme inactivation, to obtain an enzymatic hydrolysate; 5) centrifuging the enzymatic hydrolysate, and performing membrane filtration on centrifuged supernatant, to obtain the fish protein oligopeptide with low allergenicity and slight fishiness.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: May 22, 2018
    Assignee: CHINA NATIONAL RESEARCH INSTITUTE OF FOOD AND FERMENTATION INDUSTRIES
    Inventors: Muyi Cai, Ruizeng Gu, Jun Lu, Tao Ma, Xingchang Pan, Zhe Dong, Yong Ma, Yaguang Xu, Yongqing Ma, Zhentao Jin, Liang Chen, Lu Lu, Wenying Liu, Ying Wei, Haixin Zhang, Yan Liu, Kelu Cao, Jing Wang, Guoming Li, Ming Zhou
  • Patent number: 9932392
    Abstract: The invention relates to compositions and methods to prevent enteric infection in a subject at risk of such infection. In particular, the invention relates to the prevention of recurrence of infection by Clostridium difficile.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: April 3, 2018
    Assignees: CSL BEHRING AG, BETH ISRAEL DEACONESS MEDICAL CENTER INC
    Inventors: Ciaran Kelly, Xinhua Chen, Sylvia Miescher, Martin Spycher, Sandra Wymann, Adrian Zuercher
  • Patent number: 9925257
    Abstract: The present invention relates to a new vaccine delivery system. In particular, the present invention includes compositions and methods of integrally transformed non-pathogenic, commensal bacteria that can express a nucleic acid molecule of a foreign polypeptide, wherein the nucleic acid molecule that encodes the foreign polypeptide is stably integrated into genomic DNA of the bacteria. The foreign polypeptide includes a vaccine antigen that elicits an immunogenic response, an inhibitor of a pathogen, or an immune booster or modulator.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: March 27, 2018
    Assignee: Forsyth Dental Infirmary for Children
    Inventors: Antonio Campos-Neto, Mark Cayabyab, Margaret Duncan
  • Patent number: 9884108
    Abstract: The present invention relates to a new vaccine delivery system. In particular, the present invention includes compositions and methods of integrally transformed non-pathogenic, commensal bacteria that can express a nucleic acid molecule of a foreign polypeptide, wherein the nucleic acid molecule that encodes the foreign polypeptide is stably integrated into genomic DNA of the bacteria. The foreign polypeptide includes a vaccine antigen that elicits an immunogenic response, an inhibitor of a pathogen, or an immune booster or modulator.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: February 6, 2018
    Assignee: Forsyth Dental Infirmary for Children
    Inventors: Antonio Campos-Neto, Mark Cayabyab, Margaret Duncan
  • Patent number: 9789144
    Abstract: An extract of Carica papaya leaves obtained from a plant of age six months and younger from the date of germination of the seed is used as an inhibitor of HIF to effectively block hypoxia-inducible factor (HIF) function and methods of use thereof. More specifically it relates to the use of the Carica papaya plant extract to eliminate unwanted cells by inhibiting HIF in the prevention and treatment of hypoxia-related conditions and diseases such as inflammatory diseases, vascular diseases, cancer and infectious diseases. In a particular embodiment, a solid hypoxic tumor in a patient is treated by administering to the patient a therapeutically acceptable amount of an extract of Carica papaya leaves obtained from a plant of age six months and younger from the date of germination of the seed, preferably an alcohol extract such as a methanol extract, whereby to inhibit hypoxia-inducible factors in the tumor.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 17, 2017
    Assignees: The Regents of the University of California, Universiti Pultra Malaysia
    Inventors: Eric J. Stanbridge, Norazizah Shafee, Khatijah Yusoff
  • Patent number: 9670466
    Abstract: Replicons of pestiviruses, in particular replicons of swine fever virus, are engineered to have a defective replication thereby having lost infectivity, and further containing a foreign gene. A replicon contains all the genetic information required for its replication, but lacks essential codons or all codons of at least one of the genes encoding the viral structural proteins E1, E2, Ems or C protein, and consequently cannot generate infectious virus particles. Particular replicons are generated with a mutated gene encoding a modified Npro protein that no longer controls the cell interferon-induction pathway. Another particular replicon lacks the genes encoding all the structural proteins, the p7 protein and the NS2 protein, and has cytopathogenic properties in transduced cells. The replicons provide a new vector system that can be used for vaccination, gene delivery and gene therapy applications in mammals, including humans, as naked RNA or packaged into any form of delivery vehicle.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: June 6, 2017
    Assignee: INSTITUT FUR VIRUSKRANKHEITEN UND IMMUNPROPHYLAXE
    Inventors: Jon Duri Tratschin, Nicolas Ruggli, Kenneth Charles McCullough
  • Patent number: 9611310
    Abstract: The present invention provides methods of reducing nonprocessed Factor VIII or a chimeric polypeptide comprising Factor VIII comprising co-transfecting in a host cell a polynucleotide encoding Factor VIII with a polynucleotide encoding a protein convertase, where the endogenous processing enzymes of the host cell are insufficient to convert all of the Factor VIII to its processed isoform; expressing a proprotein convertase from a second polynucleotide in the host cell; and reducing the nonprocessed Factor VIII by processing with said proprotein convertase.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: April 4, 2017
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Susan C. Low, Robert T. Peters
  • Patent number: 9206410
    Abstract: Compositions and methods for preparing plasminogen, in particular recombinant plasminogen, and compositions and methods of utilizing same for preparing plasmin are provided.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: December 8, 2015
    Assignee: GRIFOLS THERAPEUTICS INC.
    Inventors: Edward Koepf, Myles Lindsay, Rebecca Silverstein, Jennifer Hunt, James Rebbeor, Thomas Zimmerman, Charles Miller, Anthony Caronna, Kenya Stokes
  • Patent number: 9017957
    Abstract: An object of the present invention is to provide an antibody that can be stably supplied and can react with prostasin under non-denaturation and denaturation conditions, and an antigen peptide for preparation of the antibody. The present invention relates to a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a peptide consisting of an amino acid sequence that has a deletion, a substitution, or an addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1 and having antigenicity of prostasin. Furthermore, the present invention relates to an antibody prepared using the peptide as an antigen.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: April 28, 2015
    Assignees: Hitachi Chemical Company, Ltd., Kimio Tomita, Kenichiro Kitamura
    Inventors: Hiromi Iijima, Noriya Ohta, Kimio Tomita, Kenichiro Kitamura
  • Publication number: 20150093495
    Abstract: A method for producing a secreted recombinant polypeptide sequence is provided. In some embodiments it comprises providing a recombinant microorganism comprising a recombinant nucleic acid comprising a first nucleic acid sequence encoding the recombinant polypeptide sequence operatively linked to a second nucleic acid sequence encoding a signal peptide; and culturing the recombinant microorganism in a culture medium under conditions sufficient for production and secretion of the recombinant protein by the recombinant microorganism. In some embodiments the coding sequence for the signal peptide is not native to the recombinant microorganism. In some embodiments the recombinant microorganism is photo synthetic. Also provided are recombinant photosynthetic microorganisms, isolated polypeptides comprising a signal peptide comprising an amino acid sequence disclosed herein, and isolated nucleic acids comprising a coding sequence for one of the signal peptides, among other things.
    Type: Application
    Filed: April 29, 2013
    Publication date: April 2, 2015
    Applicant: Pronutria, Inc.
    Inventors: Gaozhong Shen, David M. Young, Subhayu Basu, Katherine G. Gora, Carine Robichon-Iyer, Nathaniel W. Silver, David Arthur Berry
  • Patent number: 8993334
    Abstract: The present invention provides methods for separating proteins from a protein mixture. In one aspect, a method for separating a high concentration protein mixture into a bound protein fraction and a flow-through protein fraction can include delivering a protein mixture through an ion exchange column at a fixed pH and a fixed salt concentration. The fixed pH and the fixed salt concentration have been preselected to cause separation of the protein mixture into a bound protein fraction and a flow-through protein fraction. In this case, the bound protein fraction binds to the ion exchange column and the flow-though protein fraction flows though the ion exchange column. The method can further include receiving the flow-through protein fraction from the ion exchange column separate from the bound protein fraction, wherein either the bound protein fraction or the flow-through fraction contains a protein of interest.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: March 31, 2015
    Inventor: Anthony R. Torres
  • Publication number: 20150079072
    Abstract: The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides.
    Type: Application
    Filed: July 25, 2012
    Publication date: March 19, 2015
    Applicant: Biogen Idec Hemophilia Inc.
    Inventors: Jurg Sommer, Haiyan Jiang, Xin Zhang, Buyue Yang, Glenn Pierce
  • Publication number: 20150079633
    Abstract: The present invention relates to lower eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar and sugar nucleotide transporters to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified lipid-linked oligosaccharides are created or selected. N-glycans made in the engineered host cells exhibit GnTIV, GnTV, GnT VI or GnTIX activity, which produce multiantennary N-glycan structures and may be modified further by heterologous expression of one or more enzymes, e.g., glycosyltransferases, sugar, sugar nucleotide transporters, to yield human-like glycoproteins. For the production of therapeutic proteins, this method may be adapted to engineer cell lines in which any desired glycosylation structure may be obtained.
    Type: Application
    Filed: July 25, 2014
    Publication date: March 19, 2015
    Inventors: Piotr Bobrowicz, Stephen R. Hamilton, Tillman U. Gerngross, Stefan Wildt, Byung-Kwon Choi, Juergen Hermann Nett, Robert C. Davidson
  • Patent number: 8980814
    Abstract: An automatic dishwashing detergent composition comprising: a. at least 0.1 mg of active protease per gram of composition, wherein the protease is a variant of a protease that has at least 70% identity with the amino acid sequence of SEQ ID NO:1. wherein said variant comprise variations in one or more of the following positions: 32, 33, 48-54, 58-62, 94-107, 116, 123-133, 150, 152-156, 158-161, 164, 169, 175-186, 197, 198, 203-216 as compared with the protease in SEQ ID NO:1; and b. at least 0.05 mg of an active low temperature amylase per gram of composition.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: March 17, 2015
    Assignee: The Procter & Gamble Company
    Inventor: Philip Frank Souter
  • Publication number: 20150072380
    Abstract: The present invention relates to the identification of novel nucleic acid sequences, designated herein as 7p, 8k, 7E, 9G, 8Q and 203, in a host cell which effect protein production. The present invention also provides host cells having a mutation or deletion of part or all of the gene encoding 7p, 8k, 7E, 9G, 8Q and 203, which are presented in FIG. 1, and are SEQ ID NOS.: 1-6, respectively. The present invention also provides host cells further comprising a nucleic acid encoding a desired heterologous protein such as an enzyme.
    Type: Application
    Filed: September 23, 2014
    Publication date: March 12, 2015
    Applicant: DANISCO US INC.
    Inventors: Elizabeth A. Bodie, Steve Kim
  • Patent number: 8974843
    Abstract: Method of reducing the mTOR pathway stimulating activity of amino acid containing nutritional materials. This method comprises treating an enzymatically hydrolyzed protein material such as casein, whey, or soy protein with at least one enzyme capable of converting mTOR pathway stimulating amino acids and amino acid residues, such as leucine or methionine, into alternate chemical entities that do not stimulate or stimulate to a significantly lesser degree the mTOR pathway, while preserving the non-mTOR stimulating amino acids. These one or more alternate chemical entities should ideally be suitable for consumption, or alternatively be capable of being removed from the treated material through low cost extraction or conversion techniques. The material may then be sold as is, or alternatively packaged with low glycemic carbohydrates, healthy lipids, vitamins, and flavors and sold as a variety of different food products intended for an artificial diet intended to mimic the effects of caloric restriction.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: March 10, 2015
    Inventor: Ronald E. Rosedale
  • Publication number: 20150064751
    Abstract: The embodiments described herein pertain to cells, and methods for preparing cells, that can be used as biocatalysts by altering enzymes that compete for a substrate or product of a pathway of interest such that the targeted enzyme is sensitive to a site-specific protease, which protease is expressed but relocated in the cell to a site where it is not in contact with the targeted enzyme in the intact cell. Upon cell lysis, the protease contacts the target enzyme, which is then inactivated by protease cleavage.
    Type: Application
    Filed: November 14, 2014
    Publication date: March 5, 2015
    Applicants: The Board of Trustees of the Leland Stanford Junior University, GreenLight Biosciences, Inc.
    Inventor: James R. Swartz
  • Patent number: 8969062
    Abstract: The present invention provides a mutant 27 kDa NIa proteinase having reduced self-cleavage activity relative to the self-cleavage activity of its wild-type proteinase. The mutant has the same substrate cleavage activity as the wild-type proteinase but is more stable than the wild-type proteinase. The present invention also provides a method of obtaining large quantities of active 27 kDa NIa proteinase for use as a tool for purification of other proteins.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: March 3, 2015
    Assignee: Yale University
    Inventors: Jennifer A. Doudna, Louise J. Lucast, Robert T. Batey
  • Patent number: 8956848
    Abstract: A UBP1 protease mutant and the sequence coding it, their application and products and the methods used to produce them may be used in the production of recombinant proteins, particularly on an industrial scale.
    Type: Grant
    Filed: November 1, 2005
    Date of Patent: February 17, 2015
    Assignee: Instytut Biotechnoloii I Antybiotykow
    Inventors: Andrzej Plucienniczak, Anna Wojtowicz, Diana Mikiewicz-Sygula, Grazyna Plucienniczak
  • Patent number: 8956847
    Abstract: The invention provides a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a target cell; a Targeting Moiety that is capable of binding to a Binding Site on the target cell, which Binding Site is capable of undergoing endocytosis to be incorporated into an endocome within the target cell; a protease cleaving site at which site the fusion protein is cleavable by the protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and the translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the target cell.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: February 17, 2015
    Assignee: Syntaxin Limited
    Inventors: Keith Alan Foster, John Chaddock, Philip Marks, Patrick Stancombe, Lyndsey Durose
  • Publication number: 20150044195
    Abstract: Disclosed are disulphide-linked complexes of a soluble Tissue Factor (sTF) variant of SEQ ID NO:3 comprising the mutation G109C and a Factor VIIa variant of SEQ ID NO. 1, comprising the mutation Q64C and a mutation at position M306 that gives rise to a zymogen-like conformation in the Factor VIIa polypeptide. Said complexes may be used for the treatment of a coagulopathy.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 12, 2015
    Applicant: NOVO NORDISK HEALTHCARE AG
    Inventors: Henrik Oestergaard, Anders Laerke Nielsen, Ole Hvilsted Olsen
  • Publication number: 20150037872
    Abstract: The present invention relates to a method of selecting a protein variant having modified immunogenicity as compared to the parent protein comprising the steps obtaining antibody binding peptide sequences, using the sequences to localise epitope sequences on the 3-dimensional structure of parent protein, defining an epitope area including amino acids situated within 5 ? from the epitope amino acids constituting the epitope sequence, changing one or more of the amino acids defining the epitope area of the parent protein by genetical engineering mutations of a DNA sequence encoding the parent protein, introducing the mutated DNA sequence into a suitable host, culturing said host and expressing the protein variant, and evaluating the immunogenicity of the protein variant using the parent protein as reference. The invention further relates to the protein variant and use thereof, as well as to a method for producing said protein variant.
    Type: Application
    Filed: October 15, 2014
    Publication date: February 5, 2015
    Inventors: Erwin Ludo Roggen, Steffen Ernst, Allan Svendsen, Esben Peter Friis, Claus Von Der Osten
  • Publication number: 20150037842
    Abstract: The disclosure relates to a Gram negative bacterial cell that is transformed with a nucleic acid molecule that encodes a Gram positive twin-arginine translocase and including methods for the production of polypeptides.
    Type: Application
    Filed: February 22, 2013
    Publication date: February 5, 2015
    Inventor: Colin Robinson
  • Patent number: 8945855
    Abstract: Provided are methods for protein engineering, such as engineering proteases or kinases. The methods may utilize yeast display and/or ER sequestration of proteins or substrates. In some aspects, TEV proteases with altered substrate specificity, potency, and/or efficiency are provided.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: February 3, 2015
    Assignee: Research Development Foundation
    Inventors: Brent L. Iverson, George Georgiou, Joseph M. Taft, Li Yi
  • Publication number: 20150023944
    Abstract: A method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease or related dysautonomic disorders and for determining whether an individual will benefit from the administration of pancreatic/digestive enzymes to treat the dysautonomic disorder.
    Type: Application
    Filed: September 23, 2014
    Publication date: January 22, 2015
    Inventor: Joan M. Fallon
  • Publication number: 20150024465
    Abstract: The present invention relates to non-catalytic carbohydrate-binding modules (CBM) belonging to a new family of CBM's. A CBM of the invention was found attached to a glycosyl hydrolase family 61 (GH61) polypeptide and was shown to have little homology with known CBM's indicating that it is the first known member of a new family of CBM's. The present invention further relates to CBM's preferably exhibiting binding affinity for cellulose; to a method of producing such CBM's; and to methods for using such CBM's in the textile, detergent and cellulose fiber processing industries, for purification of polypeptides, immobilisation of active enzymes, baking, manufacturing of biofuel, modification of plant cell walls.
    Type: Application
    Filed: September 29, 2014
    Publication date: January 22, 2015
    Inventors: Kirk Matthew Schnorr, Lars Lehmann Hylling Christensen
  • Publication number: 20150020238
    Abstract: The present invention provides a synthetic gene encoding the human enterokinase light chain protein, a recombinant vector comprising the synthetic gene encoding the protein, a plant cell transformed with the recombinant vector, a method for producing the human enterokinase light chain protein in a plant by using the recombinant vector, a method for producing a plant producing the human enterokinase light chain protein by transforming a plant cell with the recombinant vector, a plant producing the human enterokinase light chain protein which is produced by the method, and a seed thereof, and a composition for large-scale production of the human enterokinase light chain protein in a plant, in which the composition comprises the synthetic gene encoding the human enterokinase light chain protein.
    Type: Application
    Filed: July 19, 2012
    Publication date: January 15, 2015
    Applicant: NBM CO., LTD.
    Inventor: Tae Ho Kwon